中国组织工程研究 ›› 2021, Vol. 25 ›› Issue (13): 2070-2078.doi: 10.3969/j.issn.2095-4344.2196
• 干细胞综述 stem cell review • 上一篇 下一篇
毛 鑫1,余丽梅2,3,4,5,王 峰1
收稿日期:
2020-04-22
修回日期:
2020-04-25
接受日期:
2020-06-03
出版日期:
2021-05-08
发布日期:
2020-12-28
通讯作者:
王峰,副教授,硕士,硕士研究生导师,遵义医科大学第二附属医院胸心外科,贵州省遵义市 563000
作者简介:
毛鑫,男,1995年生,贵州省遵义市人,汉族,遵义医科大学在读硕士,主要从事胸心血管外科基础研究。
基金资助:
Mao Xin1, Yu Limei2, 3, 4, 5, Wang Feng1
Received:
2020-04-22
Revised:
2020-04-25
Accepted:
2020-06-03
Online:
2021-05-08
Published:
2020-12-28
Contact:
Wang Feng, Associate professor, Master, Master’s supervisor, Department of Cardiothoracic Surgery, Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
About author:
Mao Xin, Master candidate, Department of Cardiothoracic Surgery, Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Supported by:
摘要:
文题释义:
心脏移植免疫耐受:心脏移植后,受者对供者来源的MHC抗原能产生细胞和体液免疫排斥反应,一般以细胞免疫为主。通过不同方式对宿主免疫系统识别同种异体抗原进行干扰,从而达到宿主对移植物异型抗原产生特异性免疫无反应(免疫耐受),达到移植物长期存活。
间充质干细胞来源的胞外囊泡:主要包括外泌体和微囊泡,它们包裹着大量的生物活性因子,包括蛋白质(细胞因子、膜受体、生长因子和酶)和遗传物质(mRNA和microRNAs)。间充质干细胞来源胞外囊泡是间充质干细胞发挥免疫调节和组织再生功能的主要生物因子,在心脏移植免疫耐受诱导过程中也发挥重要作用。
背景:心脏移植是终末期心脏疾病的重要治疗方式,移植后的维持离不开免疫抑制药物的使用。鉴于免疫抑制药物的不良反应较大,甚至可能对宿主生活质量产生巨大影响,人们开始探寻新的诱导移植耐受的方法,来尽量规避免疫抑制药物的使用。间充质干细胞的免疫调节特性受到了研究人员的关注,并开展了大量的相关研究。
目的:总结并探讨间充质干细胞的免疫调节特点和心脏移植免疫耐受诱导方面的问题,以及它们之间的关系。
方法:检索PubMed数据库中相关文献,时间不限。检索词包括“stem cell; mesenchymal stem cells;MSC;MSCs;heart transplantation;cardiac allograft;heart allograft;immune tolerance;tolerance;immunological rejection”。筛选排除重复研究,对相关研究文献进行整理总结并综述。
结果与结论:一方面,间充质干细胞对免疫系统各细胞有着不同的作用;另一方面,间充质干细胞调控或直接产生的众多生物活性因子构成了复杂的网络,创造了一个利于免疫调节的微环境。间充质干细胞在心脏移植中的应用多局限在动物实验,且结果都相对乐观。研究人员对心脏移植免疫耐受诱导的探究,有助于人们对该领域的进一步了解,并给相关临床工作更多的启示。
https://orcid.org/0000-0002-3556-3933(毛鑫)
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
中图分类号:
毛 鑫, 余丽梅, 王 峰. 间充质干细胞在心脏移植免疫耐受诱导中的重要作用[J]. 中国组织工程研究, 2021, 25(13): 2070-2078.
Mao Xin, Yu Limei, Wang Feng. Important role of mesenchymal stem cells in immune tolerance induction in heart transplantation[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(13): 2070-2078.
[1] KRAMPERA M, GALIPEAU J, SHI Y, et al. Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013;15(9): 1054-1061. [2] QUARANTA P, FOCOSI D, FREER G, et al. Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines. Stem Cells Dev. 2016;25(18):1321-1341. [3] VOISIN C, CAUCHOIS G, REPPEL L, et al. Are the Immune Properties of Mesenchymal Stem Cells from Wharton’s Jelly Maintained during Chondrogenic Differentiation? J Clin Med. 2020;9(2):423. [4] JIANG X, LIU C, HAO J, et al. CD4(+)CD25 (+) regulatory T cells are not required for mesenchymal stem cell function in fully MHC-mismatched mouse cardiac transplantation. Cell Tissue Res. 2014;358(2):503-514. [5] KLYUSHNENKOVA E, MOSCA JD, ZERNETKINA V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47-57. [6] GLENNIE S, SOEIRO I, DYSON PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 2005;105(7): 2821-2827. [7] PLUMAS J, CHAPEROT L, RICHARD MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 2005;19(9):1597-1604. [8] MEISEL R, ZIBERT A, LARYEA M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103(12):4619-4621. [9] SPAGGIARI GM, CAPOBIANCO A, ABDELRAZIK H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327-1333. [10] TIPNIS S, VISWANATHAN C, MAJUMDAR AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol. 2010;88(8):795-806. [11] ZHANG X, REN X, LI G, et al. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Invest Ophthalmol Vis Sci. 2011;52(6):3143-3152. [12] BERNARDO ME, FIBBE WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. [13] KAUNDAL U, BAGAI U, RAKHA A. Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation. J Transl Med. 2018;16(1):31. [14] SELMANI Z, NAJI A, ZIDI I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26(1):212-222. [15] ZHAO ZG, XU W, SUN L, et al. Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest. 2012; 41(2):183-198. [16] LIU Q, ZHENG H, CHEN X, et al. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(-) regulatory T cells. Cell Mol Immunol. 2015;12(6):708-718. [17] BEYTH S, BOROVSKY Z, MEVORACH D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5):2214-2219. [18] SPAGGIARI GM, MORETTA L. Interactions between mesenchymal stem cells and dendritic cells. Adv Biochem Eng Biotechnol. 2013;130:199-208. [19] GAO WX, SUN YQ, SHI J, et al. Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells. Stem Cell Res Ther. 2017;8(1):48. [20] SAEIDI M, MASOUD A, SHAKIBA Y, et al. Immunomodulatory effects of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on differentiation, maturation and endocytosis of monocyte-derived dendritic cells. Iran J Allergy Asthma Immunol. 2013;12(1):37-49. [21] SPAGGIARI GM, ABDELRAZIK H, BECCHETTI F, et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009;113(26):6576-6583. [22] JIANG XX, ZHANG Y, LIU B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120-4126. [23] ALDINUCCI A, RIZZETTO L, PIERI L, et al. Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol. 2010;185(9):5102-5110. [24] ZHANG W, GE W, LI C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13(3):263-271. [25] CORCIONE A, BENVENUTO F, FERRETTI E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367-372. [26] PENG Y, CHEN X, LIU Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia. 2015;29(3):636-646. [27] LIU W, ZHANG S, GU S, et al. Mesenchymal stem cells recruit macrophages to alleviate experimental colitis through TGFβ1. Cell Physiol Biochem. 2015; 35(3):858-865. [28] FRANÇOIS M, ROMIEU-MOUREZ R, LI M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187-195. [29] CHO DI, KIM MR, JEONG HY, et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med. 2014;46(1):e70. [30] LE BLANC K, MOUGIAKAKOS D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol. 2012;12(5):383-396. [31] PATEL SA, SHERMAN L, MUNOZ J, et al. Immunological properties of mesenchymal stem cells and clinical implications. Arch Immunol Ther Exp (Warsz). 2008;56(1):1-8. [32] FONTAINE MJ, SHIH H, SCHÄFER R, et al. Unraveling the Mesenchymal Stromal Cells’ Paracrine Immunomodulatory Effects. Transfus Med Rev. 2016;30(1):37-43. [33] CUERQUIS J, ROMIEU-MOUREZ R, FRANÇOIS M, et al. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation. Cytotherapy. 2014;16(2):191-202. [34] NAJAR M, RAICEVIC G, ID BOUFKER H, et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol. 2010;38(10):922-932. [35] REN G, ZHANG L, ZHAO X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2(2):141-150. [36] MA S, XIE N, LI W, et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21(2):216-225. [37] RAFFAGHELLO L, BIANCHI G, BERTOLOTTO M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26(1):151-162. [38] PREVOSTO C, ZANCOLLI M, CANEVALI P, et al. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007;92(7):881-888. [39] LE BLANC K, TAMMIK L, SUNDBERG B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11-20. [40] RASMUSSON I, RINGDÉN O, SUNDBERG B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 2003;76(8):1208-1213. [41] DI NICOLA M, CARLO-STELLA C, MAGNI M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-3843. [42] SOTIROPOULOU PA, PEREZ SA, GRITZAPIS AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006; 24(1):74-85. [43] DING Y, LIANG X, ZHANG Y, et al. Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. Cell Death Dis. 2018;9(3):386. [44] REIS M, MAVIN E, NICHOLSON L, et al. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Dendritic Cell Maturation and Function. Front Immunol. 2018;9:2538. [45] KHARE D, OR R, RESNICK I, et al. Mesenchymal Stromal Cell-Derived Exosomes Affect mRNA Expression and Function of B-Lymphocytes. Front Immunol. 2018;9:3053. [46] WU SM, ZHANG WX, WANG MH, et al. Proteomic analysis of the immunosuppressive effects of mesenchymal stem cells in a rat heart transplantation model. Adv Clin Exp Med. 2013;22(6):785-794. [47] CASIRAGHI F, AZZOLLINI N, CASSIS P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008; 181(6):3933-3946. [48] ZHOU HP, YI DH, YU SQ, et al. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc. 2006;38(9):3046-3051. [49] HUA F, CHEN Y, YANG Z, et al. Protective action of bone marrow mesenchymal stem cells in immune tolerance of allogeneic heart transplantation by regulating CD45RB+ dendritic cells. Clin Transplant. 2018;32(4):e13231. [50] WANG W, ZHAO N, LI B, et al. Inhibition of cardiac allograft rejection in mice using interleukin-35-modified mesenchymal stem cells. Scand J Immunol. 2019;89(4):e12750. [51] WANG H, QI F, DAI X, et al. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol. 2014;31(2):65-74. [52] WEISS ARR, LEE O, EGGENHOFER E, et al. Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation. Stem Cells. 2020;38(6):797-807. [53] EGGENHOFER E, RENNER P, SOEDER Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol. 2011;25(2-3):141-147. [54] GE W, JIANG J, BAROJA ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9(8):1760-1772. [55] MORMILE R. Prevention and management of allograft rejection in heart transplantation: are miR-126-5p and miR-126-5p-expressing mesenchymal stem cell exosomes the Ariadne’s thread? Cardiovasc Pathol. 2020;47:107208. [56] HE JG, XIE QL, LI BB, et al. Exosomes Derived from IDO1-Overexpressing Rat Bone Marrow Mesenchymal Stem Cells Promote Immunotolerance of Cardiac Allografts. Cell Transplant. 2018;27(11):1657-1683. [57] HE JG, LI BB, ZHOU L, et al. Indoleamine 2,3-dioxgenase-transfected mesenchymal stem cells suppress heart allograft rejection by increasing the production and activity of dendritic cells and regulatory T cells. J Investig Med. 2020;68(3):728-737. [58] HUANG H, HE J, TENG X, et al. Combined intrathymic and intravenous injection of mesenchymal stem cells can prolong the survival of rat cardiac allograft associated with decrease in miR-155 expression. J Surg Res. 2013; 185(2):896-903. [59] WU GD, NOLTA JA, JIN YS, et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation. 2003;75(5): 679-685. [60] GEORGE JF, THOMAS JM. The molecular mechanisms of veto mediated regulation of alloresponsiveness. J Mol Med (Berl). 1999;77(7):519-526. [61] GRIFFITH TS, FERGUSON TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18(5):240-244. [62] DU JF, SHEN XF, JI XQ, et al. Apoptosis of peripheral T cells in rodent cardiac allograft recipients induced by donor-specific transfusion with impaired inducible costimulator/B7 homologous protein allorecognition. Transplant Proc. 2013;45(2):564-568. [63] AIELLO S, NORIS M, PICCININI G, et al. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. J Immunol. 2000;164(9):4649-4658. [64] OLUWOLE SF, CHOWDHURY NC, JIN MX, et al. Induction of transplantation tolerance to rat cardiac allografts by intrathymic inoculation of allogeneic soluble peptides. Transplantation. 1993;56(6):1523-1527. [65] DEMIRKIRAN A, KOK A, KWEKKEBOOM J, et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 2006; 12(2):277-284. [66] HUANG Y, SHAN J, ZHANG C, et al. Peripheral blood T regulatory cell counts may not predict transplant rejection. BMC Immunol. 2010;11:40. [67] RAIMONDI G, SUMPTER TL, MATTA BM, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol. 2010;184(2):624-636. [68] MOSMANN TR, CHERWINSKI H, BOND MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348-2357. [69] ONODERA K, CHANDRAKER A, VOLK HD, et al. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation. 1999;68(2):288-293. [70] ZHENG XX, MARKEES TG, HANCOCK WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 1999;162(8):4983-4990. [71] LARSEN CP, ELWOOD ET, ALEXANDER DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438. [72] FU F, LI Y, QIAN S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation. 1996;62(5): 659-665. [73] BANCHEREAU J, BRIERE F, CAUX C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811. [74] DIETERLEN MT, JOHN K, REICHENSPURNER H, et al. Dendritic Cells and Their Role in Cardiovascular Diseases: A View on Human Studies. J Immunol Res. 2016;2016:5946807. [75] MORELLI AE, THOMSON AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7(8):610-621. [76] TANER T, HACKSTEIN H, WANG Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant. 2005;5(2):228-236. [77] PÊCHE H, TRINITÉ B, MARTINET B, et al. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant. 2005;5(2):255-267. [78] BÉRIOU G, PÊCHE H, GUILLONNEAU C, et al. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation. 2005;79(8):969-972. [79] HIKAWA H, LOTZE MT, ROSENBLUM WD. Induction of peripheral tolerance by local delivery of dendritic cell progenitors to cardiac allografts in a murine heterotopic heart transplantation model. Gen Thorac Cardiovasc Surg. 2007;55(8):307-314. [80] THIELE J, VARUS E, WICKENHAUSER C, et al. Mixed chimerism of cardiomyocytes and vessels after allogeneic bone marrow and stem-cell transplantation in comparison with cardiac allografts. Transplantation. 2004;77(12):1902-1905. [81] FÄNDRICH F, LIN X, CHAI GX, et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med. 2002;8(2):171-178. [82] URSCHEL S, RYAN LA, LARSEN IM, et al. Development of B-cell memory in early childhood and the impact on antigen-specific tolerance after heart transplantation. J Heart Lung Transplant. 2016;35(4):491-499. [83] FAN X, ANG A, POLLOCK-BARZIV SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med. 2004;10(11):1227-1233. [84] JOHN K, DIETERLEN MT, TARNOK A, et al. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients. Cytometry B Clin Cytom. 2014;86(5):362-367. [85] ODERUP C, MALM H, EKBERG H, et al. Costimulation blockade-induced cardiac allograft tolerance: inhibition of T cell expansion and accumulation of intragraft cD4(+)Foxp3(+) T cells. Transplantation. 2006;82(11): 1493-1500. [86] LISIK W, TEJPAL N, GONG Y, et al. Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. PLoS One. 2009;4(12):e8020. [87] MENARD C, PACELLI L, BASSI G, et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev. 2013;22(12):1789-1801. |
[1] | 蒲 锐, 陈子扬, 袁凌燕. 不同细胞来源外泌体保护心脏的特点与效应[J]. 中国组织工程研究, 2021, 25(在线): 1-. |
[2] | 林清凡, 解一新, 陈婉清, 叶振忠, 陈幼芳. 人胎盘源间充质干细胞条件培养液可上调缺氧状态下BeWo细胞活力和紧密连接因子的表达[J]. 中国组织工程研究, 2021, 25(在线): 4970-4975. |
[3] | 张 超, 吕 欣. 髋臼骨折固定后的异位骨化:危险因素、预防及其治疗进展[J]. 中国组织工程研究, 2021, 25(9): 1434-1439. |
[4] | 周继辉, 李新志, 周 游, 黄 卫, 陈文瑶. 髌骨骨折修复内植物选择的多重问题[J]. 中国组织工程研究, 2021, 25(9): 1440-1445. |
[5] | 王德斌, 毕郑刚. 尺骨鹰嘴骨折-脱位解剖力学、损伤特点、固定修复及3D技术应用的相关问题[J]. 中国组织工程研究, 2021, 25(9): 1446-1451. |
[6] | 姬志祥, 蓝常贡. 尿酸盐转运蛋白在痛风中的多态性和治疗相关性[J]. 中国组织工程研究, 2021, 25(8): 1290-1298. |
[7] | 袁 美, 张新新, 郭祎莎, 毕 霞. 循环microRNA在血管性认知障碍诊断中的应用[J]. 中国组织工程研究, 2021, 25(8): 1299-1304. |
[8] | 张秀梅, 翟运开, 赵 杰, 赵 萌. 类器官模型国内外数据库近10年文献研究热点分析[J]. 中国组织工程研究, 2021, 25(8): 1249-1255. |
[9] | 王正东, 黄 娜, 陈婧娴, 郑作兵, 胡鑫宇, 李 梅, 苏 晓, 苏学森, 颜 南. 丁酸钠抑制氟中毒可诱导小胶质细胞活化及炎症因子表达增多[J]. 中国组织工程研究, 2021, 25(7): 1075-1080. |
[10] | 汪显耀, 关亚琳, 刘忠山. 提高间充质干细胞治疗难愈性创面的策略[J]. 中国组织工程研究, 2021, 25(7): 1081-1087. |
[11] | 万 然, 史 旭, 刘京松, 王岩松. 间充质干细胞分泌组治疗脊髓损伤的研究进展[J]. 中国组织工程研究, 2021, 25(7): 1088-1095. |
[12] | 廖成成, 安家兴, 谭张雪, 王 倩, 刘建国. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. |
[13] | 赵 敏, 冯柳祥, 陈 垚, 顾 霞, 王平义, 李一梅, 李文华. 低氧环境下外泌体可作为疾病的标志物[J]. 中国组织工程研究, 2021, 25(7): 1104-1108. |
[14] | 谢文佳, 夏天娇, 周卿云, 刘羽佳, 顾小萍. 小胶质细胞介导神经元损伤在神经退行性疾病中的作用[J]. 中国组织工程研究, 2021, 25(7): 1109-1115. |
[15] | 李珊珊, 郭笑霄, 尤 冉, 杨秀芬, 赵 露, 陈 曦, 王艳玲. 感光细胞替代治疗视网膜变性疾病[J]. 中国组织工程研究, 2021, 25(7): 1116-1121. |
文题释义:#br# 心脏移植免疫耐受:心脏移植后,受者对供者来源的MHC抗原能产生细胞和体液免疫排斥反应,一般以细胞免疫为主。通过不同方式对宿主免疫系统识别同种异体抗原进行干扰,从而达到宿主对移植物异型抗原产生特异性免疫无反应(免疫耐受),达到移植物长期存活。#br# 间充质干细胞来源的胞外囊泡:主要包括外泌体和微囊泡,它们包裹着大量的生物活性因子,包括蛋白质(细胞因子、膜受体、生长因子和酶)和遗传物质(mRNA和microRNAs)。间充质干细胞来源胞外囊泡是间充质干细胞发挥免疫调节和组织再生功能的主要生物因子,在心脏移植免疫耐受诱导过程中也发挥重要作用。#br#
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||